Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 14/20 | 0.85 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.73 |
| ▸ | P2RY4 | P51582 | 8/20 | 0.73 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine Triphosphate SCHEMBL25298912 | 0.93 | P2RY2 (0.92) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL15082664 | 0.92 | P2RY2 (1.00) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL25248334 | 0.91 | P2RY2 (0.80) | P2RY2P2RY6P2RY4P2RY14 | |
| Cytarabine 5'-Phosphate SCHEMBL16189 | 0.91 | P2RY2 (0.69) | P2RY2P2RY6P2RY4 | |
| Cytarabine 5'-Phosphate SCHEMBL18785109 | 0.91 | P2RY2 (0.69) | P2RY2P2RY6P2RY4 | |
| Cytarabine 5'-Phosphate SCHEMBL284602 | 0.91 | P2RY2 (0.69) | P2RY2P2RY6P2RY4 | |
| Cytarabine 5'-Phosphate SCHEMBL6115643 | 0.91 | P2RY2 (0.69) | P2RY2P2RY6P2RY4 | |
| Cytarabine 5'-Phosphate SCHEMBL11217191 | 0.91 | P2RY2 (0.69) | P2RY2P2RY6P2RY4 | |
| Cytarabine 5'-Phosphate SCHEMBL2681941 | 0.91 | P2RY2 (0.69) | P2RY2P2RY6P2RY4 | |
| Cytarabine 5'-Phosphate SCHEMBL14669262 | 0.91 | P2RY2 (0.69) | P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250146005-A1 | METHODS OF MAKING CIRCULAR RNA | INNOFORCE PHARMACEUTICALS (CN) | 2025-05-08 | — | — | US | claimed |
| CN-115515968-A | Allele-specific silencing of transforming growth factor beta-inducible genes with R124H mutation using short interfering RNA | 阿维利诺美国实验室股份有限公司 | 2022-12-23 | — | — | CN | claimed |
| WO-2021117009-A2 | ALLELE-SPECIFIC SILENCING OF TRANSFORMING GROWTH FACTOR BETA INDUCED GENE WITH R124H MUTATION USING SHORT INTERFERING RNA | MOORE TARA (US) | 2021-06-17 | — | — | WO | claimed |
| US-20250146005-A1 | METHODS OF MAKING CIRCULAR RNA | INNOFORCE PHARMACEUTICALS (CN) | 2025-05-08 | — | — | US | disclosed |
| US-11969402-B2 | Compositions and methods for skin rejuvenation | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240115649-A1 | CASPASE INHIBITION TO ENHANCE REGENERATION AND REPAIR AFTER SKIN OR GUT INJURY AND TO TREAT BACTERIAL OR VIRAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-04-11 | — | — | US | disclosed |
| US-11813281-B2 | Methods for improving exercise tolerance in myalgic encephalomyelitis patients | AIM IMMUNOTECH INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813279-B2 | Compositions for cancer therapy and methods | AIM IMMUNOTECH INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230218705-A1 | CASPASE INHIBITORS TO ENHANCE INJURY REPAIR AND TO TREAT BACTERIAL AND VIRAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-13 | — | — | US | disclosed |
| US-11642396-B2 | Method of reducing antigenic drift or reassortment of viruses in a host animal using α interferon | AIM IMMUNOTECH INC. (US) | 2023-05-09 | — | — | US | disclosed |
| CN-115843270-A | Hepatitis C nucleic acid vaccine comprising E2 polypeptide deleted of variable domain | 麦克法兰布奈特医疗研究与公共健康研究所有限公司 | 2023-03-24 | — | — | CN | disclosed |
| EP-4048791-A1 | METHODS AND COMPOSITIONS FOR TREATING ENDOMETRIOSIS | Aim Immunotech Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| EP-3640328-B1 | ENZYMES | RES & INNOVATION UK (GB) | 2022-08-17 | — | — | EP | disclosed |
| US-20220233490-A1 | COMPOSITIONS AND METHODS FOR SKIN REJUVENATION | THE JOHNS HOPKINS UNIVERSITY | 2022-07-28 | — | — | US | disclosed |
| US-20220096518-A1 | COMPOSITIONS AND METHODS FOR CANCER THERAPY | AIM IMMUNOTECH INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220062321-A1 | METHODS FOR IMPROVING EXERCISE TOLERANCE IN MYALGIC ENCEPHALOMYELITIS PATIENTS | AIM IMMUNOTECH INC. (US) | 2022-03-03 | — | — | US | disclosed |
| WO-2021117009-A2 | ALLELE-SPECIFIC SILENCING OF TRANSFORMING GROWTH FACTOR BETA INDUCED GENE WITH R124H MUTATION USING SHORT INTERFERING RNA | MOORE TARA (US) | 2021-06-17 | — | — | WO | disclosed |
| US-10813940-B2 | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection | ABBOTT LABORATORIES (US) | 2020-10-27 | — | — | US | disclosed |
| US-20180008623-A1 | NUTRITIONAL COMPOSITIONS COMPRISING HUMAN MILK OLIGOSACCHARIDES AND NUCLEOTIDES AND USES THEREOF FOR TREATING AND/OR PREVENTING ENTERIC VIRAL INFECTION | ABBOTT LABORATORIES (US) | 2018-01-11 | — | — | US | disclosed |
| US-9763970-B2 | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection | ABBOTT LABORATORIES (US) | 2017-09-19 | — | — | US | disclosed |